- Home
- CTMX vs ADAP Comparison
CTMX vs ADAP Comparison
Compare CTMX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ADAP
- Stock Information
- Founded
- CTMX 2008
- ADAP 2008
- Country
- CTMX United States
- ADAP United Kingdom
- Employees
- CTMX N/A
- ADAP N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- ADAP Health Care
- Exchange
- CTMX Nasdaq
- ADAP Nasdaq
- Market Cap
- CTMX 62.3M
- ADAP 71.6M
- IPO Year
- CTMX 2015
- ADAP 2015
- Fundamental
- Price
- CTMX $0.59
- ADAP $0.23
- Analyst Decision
- CTMX Buy
- ADAP Strong Buy
- Analyst Count
- CTMX 6
- ADAP 5
- Target Price
- CTMX $5.77
- ADAP $1.83
- AVG Volume (30 Days)
- CTMX 3.8M
- ADAP 2.7M
- Earning Date
- CTMX 03-06-2025
- ADAP 05-14-2025
- Dividend Yield
- CTMX N/A
- ADAP N/A
- EPS Growth
- CTMX N/A
- ADAP N/A
- EPS
- CTMX 0.38
- ADAP N/A
- Revenue
- CTMX $138,103,000.00
- ADAP $178,032,000.00
- Revenue This Year
- CTMX N/A
- ADAP N/A
- Revenue Next Year
- CTMX N/A
- ADAP $64.04
- P/E Ratio
- CTMX $1.68
- ADAP N/A
- Revenue Growth
- CTMX 36.45
- ADAP 195.34
- 52 Week Low
- CTMX $0.56
- ADAP $0.20
- 52 Week High
- CTMX $5.85
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- CTMX 43.41
- ADAP 14.30
- Support Level
- CTMX $0.57
- ADAP $0.26
- Resistance Level
- CTMX $0.65
- ADAP $0.47
- Average True Range (ATR)
- CTMX 0.05
- ADAP 0.04
- MACD
- CTMX 0.01
- ADAP -0.02
- Stochastic Oscillator
- CTMX 51.28
- ADAP 1.40
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.